Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR L858R”

32 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 32 results

Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Early research (Phase 1)Looking for participantsNCT06955988
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 120
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Early research (Phase 1)Ended earlyNCT04862780
What this trial is testing

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+21 more
Blueprint Medicines Corporation 177
Post-approval studies (Phase 4)Study completedNCT02208843
What this trial is testing

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06827145
What this trial is testing

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
National Cancer Center, China 30
Testing effectiveness (Phase 2)Study completedNCT01933347
What this trial is testing

Third-line Treatment of Gefitinib in NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials 46
Testing effectiveness (Phase 2)WithdrawnNCT06227897
What this trial is testing

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Who this might be right for
Lung Cancer
Sun Yat-sen University
Testing effectiveness (Phase 2)Ended earlyNCT04099836
What this trial is testing

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Who this might be right for
Non Small Cell Lung Cancer
Duke University 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT05256290
What this trial is testing

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non-Small Cell Lung CancerAdvanced Non-Small Cell Squamous Lung CancerMetastatic Lung Non-Small Cell Carcinoma+7 more
Black Diamond Therapeutics, Inc. 200
Testing effectiveness (Phase 2)Looking for participantsNCT07505173
What this trial is testing

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Who this might be right for
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital 74
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Large-scale testing (Phase 3)Active Not RecruitingNCT05338970
What this trial is testing

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Who this might be right for
Nonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion
Daiichi Sankyo 586
Early research (Phase 1)Not Yet RecruitingNCT07461727
What this trial is testing

An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases

Who this might be right for
Non-Small Cell Lung CancerMetastatic Non-small Cell Lung CancerLiver Metastases+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 15
Testing effectiveness (Phase 2)Looking for participantsNCT06706076
What this trial is testing

BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics 266
Testing effectiveness (Phase 2)Study completedNCT05263947
What this trial is testing

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Who this might be right for
Carcinoma, Non-Small-Cell LungBevacizumabTyrosine Kinase Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital 35
Testing effectiveness (Phase 2)UnknownNCT04988607
What this trial is testing

Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

Who this might be right for
Lung Cancer
Guangdong Association of Clinical Trials 90
Large-scale testing (Phase 3)Active Not RecruitingNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Testing effectiveness (Phase 2)UnknownNCT01955421
What this trial is testing

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Who this might be right for
Advanced Stage Non Small Cell Lung Cancer
Sun Yat-sen University 224
Testing effectiveness (Phase 2)Looking for participantsNCT07206498
What this trial is testing

Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
Wayshine Biopharm, Inc. 48
Load More Results